Suzhou Hepathera Biotech Co., Ltd.
Clinical trials sponsored by Suzhou Hepathera Biotech Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New shot combo aims to silence hepatitis b virus Results expected Feb 2027 (estimated)
-
New shot combo aims to silence hepatitis b virus
Disease control OngoingThis study tests two experimental injections, HT-101 and HT-102, in 60 adults with chronic hepatitis B who are already on standard antiviral therapy. The goal is to see if the combination can lower hepatitis B virus levels to undetectable and help the immune system control the in…
Phase 2 • Sponsor: Suzhou HepaThera Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New shot combo aims to tame hepatitis b
Disease control OngoingThis early-stage trial tests two new injections (HT-101 and HT-102) in 86 people with chronic hepatitis B. Participants receive the shots every 4 weeks, along with standard antiviral pills. The main goal is to check safety and how the body processes the drugs, while also looking …
Phase 1/2 • Sponsor: Suzhou HepaThera Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 19:04 UTC